Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) was the target of a large growth in short interest in June. As of June 30th, there was short interest totaling 7,045 shares, a growth of 1,819.6% from the June 15th total of 367 shares. Based on an average trading volume of 8,423 shares, the short-interest ratio is presently 0.8 days.
Clinuvel Pharmaceuticals Stock Performance
Shares of OTCMKTS:CLVLY traded up $0.08 during trading on Friday, reaching $7.24. 1,042 shares of the company were exchanged, compared to its average volume of 2,799. The business’s fifty day simple moving average is $6.87 and its 200-day simple moving average is $7.31. Clinuvel Pharmaceuticals has a 12-month low of $5.98 and a 12-month high of $9.00.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
See Also
- Five stocks we like better than Clinuvel Pharmaceuticals
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
